Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 12, 2025Clinical Hematology InternationalOpen Access

Beyond Hypomethylating Agents: Novel Therapies and Targeted Approaches

View Full Paper
Ask AI
Bookmark
Share

Authors

VCViviana CortianaSVSree Harshitha VallabhaneniJGJenna Ghazal

Discussion

Loading...

Member takes

Overview

Emerging therapies improve patient outcomes in myelodysplastic syndromes, highlighting the need for precision medicine and targeted approaches.

Key Points

  • Emerging treatments boost outcomes for patients with myelodysplastic syndromes, while current options are limited.
  • Novel agents like luspatercept and imetelstat enhance transfusion independence in lower-risk myelodysplastic syndromes.
  • Clinical trials reveal the need for improved patient selection regarding immune checkpoint inhibitors in high-risk myelodysplastic syndromes.
  • The future of myelodysplastic syndrome treatment focuses on precision medicine to guide treatment based on molecular characteristics.

Cite This Study

Cortiana et al. (2025) studied this question.

synapsesocial.com/papers/68a3633d0a429f7973329de2https://doi.org/10.46989/001c.142956
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory Myelodysplastic Syndrome2021 · 17 citations
  2. 2Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms2023 · 21 citations
  3. 3Clinical significance of somatic mutation in unexplained blood cytopenia2017 · 480 citations
  4. 4Eprenetapopt (APR-246) and Azacitidine in <i>TP53</i>-Mutant Myelodysplastic Syndromes2021 · 448 citations
  5. 5Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML2022 · 36 citations